CureVac (NASDAQ:CVAC) Sees Large Volume Increase – Time to Buy?

Shares of CureVac (NASDAQ:CVAC) saw unusually-high trading volume on Friday . Approximately 1,049,276 shares were traded during trading, an increase of 29% from the previous session’s volume of 812,320 shares.The stock last traded at $3.00 and had previously closed at $2.80.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Up 6.4 %

The firm has a market capitalization of $667.16 million, a price-to-earnings ratio of 5.42 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The business’s 50 day moving average is $3.38 and its 200-day moving average is $3.19.

Institutional Investors Weigh In On CureVac

Several hedge funds and other institutional investors have recently made changes to their positions in CVAC. Barclays PLC acquired a new position in shares of CureVac during the 3rd quarter worth about $67,000. Public Employees Retirement System of Ohio acquired a new position in shares of CureVac during the third quarter worth approximately $91,000. Jane Street Group LLC boosted its position in shares of CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after acquiring an additional 4,425 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in CureVac during the third quarter worth $35,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.